Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alsertib and Brentuximab Vedotin in CD30-positive Malignancies
NCT02780011Phase 1Withdrawn
- Start
- Dec 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alisertib in CD30-positive lymphoma. Primary endpoint: Maximum Tolerated Dose at 12 weeks. Planned start Dec 2015; status: withdrawn.
02
Drugs
alisertib
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT02780011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780011.